Ad hoc: Increased license costs for extended "ZEISS" trademark utilization rights

Wednesday, 27. March 2013 09:54

Carl Zeiss Meditec AG / License Contract / Ad hoc: Increased license costs for extended "ZEISS" trademark utilization rights . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Jena, 27 March 2013: Use of the "ZEISS" trademark is of great value to the company with regard to market profile and customer awareness. With effect from 1.10.13 Carl Zeiss Meditec AG and Carl Zeiss AG will therefore conclude a new trademark license agreement which secures the longer-term use of the "ZEISS" trademark for the entire product portfolio. The existing agreement only covered compensation for trademark utilization of some of the Carl Zeiss Meditec products. Due to the fact that the agreement could be cancelled at short notice this only provided Carl Zeiss Meditec with insufficient security for utilization of the trademark rights. The new agreement covers a period of three years and includes an extension option. The agreed compensation has been extended to cover sales of all products; this will result in higher costs for the company from the 2013/14 financial year. In comparison to the existing agreement which runs until 30.9.13 (annual costs: EUR 3.4 million), the new agreement would entail an increase of approximately EUR 4.3 million on the 2012/13 licensing costs figure.

Contact for investors:
Henriette Meyer, Investor Relations, Carl Zeiss Meditec AG
Phone 03641 220-106, E-Mail:

Press contacts:
Jann Gerrit Ohlendorf, Corporate Communications, Carl Zeiss Meditec AG PhoneI03641 220-331, E-Mail:

Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2011/2012 (ended 30 September) the Group's more than 2,400 employees generated revenue of almost € 862 million. The head office of Carl Zeiss Meditec is in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
Fore more than 160 years Carl Zeiss has been contributing to the progress of technology on the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, improving the quality of life for many people. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For more information visit our website at:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Carl Zeiss Meditec AG via Thomson Reuters ONE


--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 531370;ISIN: DE0005313704;Index:Prime All Share,TECH All Share,TecDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Related Links: Carl Zeiss Meditec AG
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.